These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11764067)

  • 1. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 2. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical evaluation of HER-2 status: which test to use?
    Bartlett J; Mallon E; Cooke T
    J Pathol; 2003 Apr; 199(4):411-7. PubMed ID: 12635130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
    Egervari K; Szollosi Z; Nemes Z; Kaczur V
    Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
    Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
    J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
    Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
    [No Abstract]   [Full Text] [Related]  

  • 9. The importance of accuracy in HER2 testing.
    Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):529-31. PubMed ID: 23073051
    [No Abstract]   [Full Text] [Related]  

  • 10. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR; Stoler MH
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract]   [Full Text] [Related]  

  • 11. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
    Hugh J; Barley R; Dabbagh L
    Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
    [No Abstract]   [Full Text] [Related]  

  • 12. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 15. [Standardization of HER2 testing in gastric cancer].
    Long XY; Bu H; Liu JP
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):645-8. PubMed ID: 22177257
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality control of HER2 immunohistochemistry--results from a Hungarian study].
    Cserni G; Kálmán E; Kulka J; Orosz Z; Udvarhelyi N; Krenács T
    Magy Onkol; 2007; 51(1):23-9. PubMed ID: 17417672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
    Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
    Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
    [No Abstract]   [Full Text] [Related]  

  • 19. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistochemical assays for HER2 overexpression.
    Maia DM
    J Clin Oncol; 1999 May; 17(5):1650. PubMed ID: 10334562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.